日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Completeness and generalizability of the Swedish MS register

瑞典MS登记册的完整性和普遍适用性

Alping, Peter; Frisell, Thomas; He, Anna; Hillert, Jan; Fink, Katharina; McKay, Kyla A

Validation of the Swedish Multiple Sclerosis registry for pediatric-onset multiple sclerosis

瑞典多发性硬化症登记册对儿童期发病多发性硬化症的验证

Sandesjö, Fredrik; Alping, Peter; Fink, Katharina; Wickström, Ronny; Piehl, Fredrik; Frisell, Thomas; McKay, Kyla A

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study

多发性硬化症、疾病修饰药物与不良围产期和妊娠结局风险:一项基于人群队列研究的结果

Fink, Katharina; Gorczyca, Agnes; Alping, Peter; Englund, Simon; Farmand, Susan; Langer-Gould, Annette M; Piehl, Fredrik; McKay, Kyla; Frisell, Thomas; Razaz, Neda

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

阿仑单抗联合自体造血干细胞移植与多发性硬化症非诱导疗法相比的安全性

Alping, Peter; Burman, Joachim; Lycke, Jan; Frisell, Thomas; Piehl, Fredrik

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

接受芬戈莫德、那他珠单抗、利妥昔单抗和注射疗法治疗的多发性硬化症患者的感染风险

Luna, Gustavo; Alping, Peter; Burman, Joachim; Fink, Katharina; Fogdell-Hahn, Anna; Gunnarsson, Martin; Hillert, Jan; Langer-Gould, Annette; Lycke, Jan; Nilsson, Petra; Salzer, Jonatan; Svenningsson, Anders; Vrethem, Magnus; Olsson, Tomas; Piehl, Fredrik; Frisell, Thomas

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

利妥昔单抗治疗多发性硬化症:一项关于安全性和有效性的回顾性观察研究

Salzer, Jonatan; Svenningsson, Rasmus; Alping, Peter; Novakova, Lenka; Björck, Anna; Fink, Katharina; Islam-Jakobsson, Protik; Malmeström, Clas; Axelsson, Markus; Vågberg, Mattias; Sundström, Peter; Lycke, Jan; Piehl, Fredrik; Svenningsson, Anders